Derek is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry.
Derek Sheader
Latest news
-
LifeArc and Genetic Alliance UK launch a new report calling for the acceleration of research and development (R&D) for rare diseases
-
Innovative home monitoring service aims to improve care for patients with dementia
-
LifeArc joins new global initiative to accelerate drug discovery for ALS/MND treatments